Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | BCL3 | P20749 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876842 | 1.00 | CNR1 (0.36) | CNR1CNR2BCL3KMT2AMEN1 | |
| SCHEMBL4879578 | 0.92 | HSD11B1 (0.35) | HSD11B1MAPK14P2RX7 | |
| SCHEMBL4879571 | 0.92 | HSD11B1 (0.35) | HSD11B1MAPK14P2RX7 | |
| SCHEMBL4877510 | 0.91 | HSD11B1 (0.35) | KMT2AMEN1HSD11B1MAPK14P2RX7 | |
| SCHEMBL4877515 | 0.91 | HSD11B1 (0.35) | KMT2AMEN1HSD11B1MAPK14P2RX7 | |
| SCHEMBL4877778 | 0.90 | MAPK14 (0.38) | HSD11B1MAPK14 | |
| SCHEMBL4877782 | 0.90 | MAPK14 (0.38) | HSD11B1MAPK14 | |
| SCHEMBL4876860 | 0.89 | ACKR3 (0.39) | HSD11B1MAPK14 | |
| SCHEMBL4876865 | 0.89 | ACKR3 (0.39) | HSD11B1MAPK14 | |
| SCHEMBL4874582 | 0.89 | MAPK14 (0.39) | HSD11B1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081825-A1 | Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-03 | — | — | US | disclosed |
| EP-1741702-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081825-A1 | Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof | MAPK1, NOS1, NOS2 | CNR1 1524/4885CNR2 1501/4885BCL3 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.